Medindia LOGIN REGISTER
Medindia
Advertisement

BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test

Wednesday, September 24, 2008 General News
Advertisement
REHOVOT, Israel, September 24 BioView Ltd,(TASE: BIOV) from Rehovot, Israel, reported today results of its internalclinical trial of the non-invasive diagnostic test under development forearly detection of lung cancer.
Advertisement

In the trial a total of 76 sputum samples were collected from four groupsof patients:

The sputum samples were blindly scanned and analyzed morphologically andgenetically, with fluorescent probes exclusively licensed to BioView, onBioView's automated Duet scanning station by Company personnel. The resultsof the test were classified as "Normal", i.e. no cancer detected and"Abnormal", i.e. Cancer detected. These results were then compared to theactual data received from the hospital of the patients' condition.
Advertisement

The samples included 32 cases of lung cancer patients (about half of themearly stage patients) and 44 samples taken from people with no clinicalevidence of lung cancer. Thirty one of the thirty two (96.9%) sick patientswere correctly diagnosed as "Abnormal" and thirty six of forty four (about82%) healthy people were correctly diagnosed as "Normal".

Project leader, Dr. Michal Daniely says:"We have gained great confidencein this test as we see a direct relationship between our results and theclinical status of the patients".

Dr. Opher Shapira, BioView's CEO commented: "We are extremely pleasedwith the results; the specificity and sensitivity in this test are betterthan other non-invasive tests presently available for early lung cancerdetection. We are accelerating our development efforts to improve theseresults as well as to increase our sample size and to include otherlaboratories in the clinical trials."

BioView lung cancer test in based on morphological and genetic analysisof sputum samples and it is running on BioView DUETTM automated scanningplatform.

About BioView Ltd.

Established in 2000, and led by an expert team of biologists, softwareengineers and physicists, BioView develops, manufactures and supplies cellimaging equipment, biological kits and software to medical institutes anduniversities. BioView is a publicly traded company on the Israeli Stockexchange, and currently has strategic collaborations underway withinternational scientific leaders and institutions. For more information aboutthe BioView technology, and press related issues, please [email protected] or visit our website at http://www.bioview.co.il.1. Healthy individuals that never smoked 2. Heavy smokers with no signs of lung cancer 3. Early stage lung cancer patients (Stage 1) 4. Advanced stage lung cancer patients

SOURCE BioView Ltd
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close